D Carroll1, C Ring, M Suter, G Willemsen. 1. School of Sport and Exercise Sciences, University of Birmingham, UK. carrolld@bham.ac.uk
Abstract
RATIONALE: Vitamin and mineral supplements may be associated with improved psychological status. OBJECTIVE: The present study tested the effects of a multivitamin and mineral supplement (Berocca) on psychological well-being. METHODS: In a double-blind randomised-control trial, 80 healthy male volunteers were assigned to either Berocca or placebo. Questionnaires measuring psychological state were completed and a blood sample taken to determine plasma zinc concentration on day 1 (pre-treatment) and again on day 28 (post-treatment), following 28 days of treatments, which were administered at a dosage of one tablet daily. At the end of the study, the acceptability of the treatment and participants' awareness of treatment condition were assessed, as was habitual dietary behaviour. RESULTS: Relative to placebo, treatment with Berocca was associated with consistent and statistically significant reductions in anxiety and perceived stress. Participants in the Berocca group also tended to rate themselves as less tired and better able to concentrate following treatment. In addition, participants registered more somatic symptoms following placebo than following Berocca. These effects cannot be attributed to differences in the acceptability of the two treatments or to participants guessing what treatment they received. CONCLUSION: These findings demonstrate that Berocca significantly reduces anxiety and perceived stress.
RCT Entities:
RATIONALE: Vitamin and mineral supplements may be associated with improved psychological status. OBJECTIVE: The present study tested the effects of a multivitamin and mineral supplement (Berocca) on psychological well-being. METHODS: In a double-blind randomised-control trial, 80 healthy male volunteers were assigned to either Berocca or placebo. Questionnaires measuring psychological state were completed and a blood sample taken to determine plasma zinc concentration on day 1 (pre-treatment) and again on day 28 (post-treatment), following 28 days of treatments, which were administered at a dosage of one tablet daily. At the end of the study, the acceptability of the treatment and participants' awareness of treatment condition were assessed, as was habitual dietary behaviour. RESULTS: Relative to placebo, treatment with Berocca was associated with consistent and statistically significant reductions in anxiety and perceived stress. Participants in the Berocca group also tended to rate themselves as less tired and better able to concentrate following treatment. In addition, participants registered more somatic symptoms following placebo than following Berocca. These effects cannot be attributed to differences in the acceptability of the two treatments or to participants guessing what treatment they received. CONCLUSION: These findings demonstrate that Berocca significantly reduces anxiety and perceived stress.
Authors: David O Kennedy; Rachel Veasey; Anthony Watson; Fiona Dodd; Emma Jones; Silvia Maggini; Crystal F Haskell Journal: Psychopharmacology (Berl) Date: 2010-05-08 Impact factor: 4.530
Authors: J Steven A Simpson; Susan G Crawford; Estelle T Goldstein; Catherine Field; Ellen Burgess; Bonnie J Kaplan Journal: BMC Psychiatry Date: 2011-04-18 Impact factor: 3.630
Authors: Jerome Sarris; Katherine H M Cox; David A Camfield; Andrew Scholey; Con Stough; Erin Fogg; Marni Kras; David J White; Avni Sali; Andrew Pipingas Journal: Nutr J Date: 2012-12-14 Impact factor: 3.271
Authors: J Sarris; S Moylan; D A Camfield; M P Pase; D Mischoulon; M Berk; F N Jacka; I Schweitzer Journal: Evid Based Complement Alternat Med Date: 2012-08-27 Impact factor: 2.629